References
- Aggarwal BB, Danda D, Gupta S, Gehlot P. Models for prevention and treatment of cancer: problems vs promises. Biochem Pharmacol. 2009;78:1083–94. doi:https://doi.org/10.1016/j.bcp.2009.05.027
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:https://doi.org/10.3322/caac.21492
- Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015;33(35):4210–8. doi:https://doi.org/10.1200/JCO.2015.62.4718
- Cortes J, Digumarti R, Parikh PM, Wetzler M, Lipton JH, Hochhaus A, Craig AR, Benichou A-C, Nicolini FE, Kantarjian HM, et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukaemia patients resistant to or intolerant of tyrosine kinase inhibitors. Am. J. Hematol. 2013;88:350–4. doi:https://doi.org/10.1002/ajh.23408
- Chen Y, Hu Y, Michaels S, Segal D, Brown D, Li S. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Leukaemia. 2009;23(8):1446–54. doi:https://doi.org/10.1038/leu.2009.52
- Dančík V, Seiler KP, Young DW, Schreiber SL, Clemons PA. Distinct biological network properties between the targets of natural products and disease genes. J Am Chem Soc. 2010;132(27):9259–61. doi:https://doi.org/10.1021/ja102798t
- Kinch MS, Haynesworth A, Kinch SL, Hoyer D. An overview of FDA-approved new molecular entities: 1827–2013. Drug Discov Today. 2014;19(8):1033–9. doi:https://doi.org/10.1016/j.drudis.2014.03.018
- Pourianezhad F, Tahmasebi S, Abdusi V, Nikfar S, Mirhoseini M. Review on feverfew, a valuable medicinal plant. J HerbMed Pharmacol. 2016;5(2):45–9.
- Pareek A, Suthar M, Rathore GS, Bansal V. Feverfew (Tanacetum parthenium L.): A systematic review. Phcog Rev. 2011;5:103–110. doi:https://doi.org/10.4103/0973-7847.79105
- Omidbeigi R. Production and processing of medicinal plants. 4th ed.Mashhad: Astane-e-Ghods-e-Razavi Press; 2007. p. 256–67.
- Chavez M, Chavez P. Feverfew. Hosp Pharm. 1999;34(4):436–61. doi:https://doi.org/10.1177/001857879903400408
- Kumar V, Tyagi D. Chemical composition and biological activities of essential oils of Genus Tanacetum - a review. J Pharmacogn Phytochem. 2013;2(3):159–63.
- Hobbs CR. Feverfew (Tanacetum parthenium). Herbalgrm. 1999;20:267–70.
- Setty AR, Sigal AH. Herbal medications commonly used in the practice of rheumatology: Mechanisms of action, efficacy, and side effects. Semin Arthritis Rheum. 2005;34:773–84. doi:https://doi.org/10.1016/j.semarthrit.2005.01.011
- Cumo C. Encyclopedia of Cultivated Plants A-F. Santa Barbara: ABC-CLIO. 2013. p. 329–32.
- Kisiel W, Stojakowska A. Sesquiterpene coumarin ether from transformed roots of Tanacetum parthenium. Phytochemistry. 1997;46(3):515–6. doi:https://doi.org/10.1016/S0031-9422(97)87091-4
- Groenewegen WA, Knight DW, Heptinstall S. Compounds extracted from feverfew that have anti-secretory activity contain an alpha-methylene butyrolactone unit. J Pharm Pharmacol. 1986;38:709–12. doi:https://doi.org/10.1111/j.2042-7158.1986.tb03118.x
- Milbrodt M, Schroder F, Konig W. 3,4–Epoxy-8-deoxycumambrin B, A sesquiterpene lactone from Tanacetum parthenium. Phytochemistry. 1997;44(3):471–4. doi:https://doi.org/10.1016/S0031-9422(96)00555-9
- Mathema VB, Koh YS, Thakuri BC, Sillanpää M. Parthenolide, a sesquiterpene lactone, expresses multiple anti-cancer and anti-inflammatory activities. Inflammation. 2012;35:560. doi:https://doi.org/10.1007/s10753-011-9346-0
- Guzman ML, Rossi RM, Karnischky L, Li X, Peterson DR, Howard DS. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukaemia stem and progenitor cells. Blood. 2005;105:4163–9. doi:https://doi.org/10.1182/blood-2004-10-4135
- Flores-Lopez G, Mayani H, Chavez- Gonzalez MA. Parthenolide and DMAPT induce cell death in chronic myeloid leukaemia cells via generation of reactive oxygen species. Blood. 2016;128(22):4242. doi:https://doi.org/10.1182/blood.V128.22.4242.4242
- Zunino SJ, Ducore JM, Storms DH. Parthenolide induces significant apoptosis and production of reactive oxygen species in high-risk pre-B leukaemia cells. Cancer Lett. 2007;254(1):119–27. doi:https://doi.org/10.1016/j.canlet.2007.03.002
- Mohsenzadeh F, Chehregani A, Amiri H. Chemical composition, antibacterial activity and cytotoxicity of essential oils of Tanacetum parthenium in different developmental stages. Pharm Biol. 2011;49(9):920–926. doi:https://doi.org/10.3109/13880209.2011.556650
- Kwok BH, Koh B, Ndubuisi MI, Crews CM. The anti-inflammatory natural product parthenolide from the medicinal herb feverfew directly binds to and inhibits Ikappab kinase. Chem Biol. 2001;8(8):759–766. doi:https://doi.org/10.1016/S1074-5521(01)00049-7
- Ross JJ, Arnason JT, Birnboim HC. Low concentrations of the feverfew component parthenolide inhibit in vitro growth of tumour lines in a cytostatic fashion. Planta Med. 1999;65:126–9. doi:https://doi.org/10.1055/s-1999-13972
- Siveen KS, Uddin S, Mohammad RM. Targeting acute myeloid leukaemia stem cell signalling by natural products. Mol Cancer. 2017;16(1):13. doi:https://doi.org/10.1186/s12943-016-0571-x
- Miglietta A, Bozzo F, Gabriel L, Bocca C. Microtubule-interfering activity of parthenolide. Chem Biol Interact. 2004;149:165–73. doi:https://doi.org/10.1016/j.cbi.2004.07.005
- Zhang D, Qiu L, Jin X, Guo Z, Guo C. Nuclear factor-κB inhibition by parthenolide potentiates the efficacy of taxol in non–small cell lung cancer in vitro and in vivo. Mol Cancer Res. 2009;7(7):1139–49. doi:https://doi.org/10.1158/1541-7786.MCR-08-0410
- Curry Iii EA, Murry DJ, Yoder C, Fife K, Armstrong V, Nakshatri H, O’Connell M, Sweeney CJ. Phase I dose-escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Invest New Drugs. 2004;22(3):299–305. doi:https://doi.org/10.1023/B:DRUG.0000026256.38560.be
- Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC, Becker MW, Bennett JM, Sullivan E, Lachowicz JL, et al. An orally bioavailable parthenolide analogue selectively eradicates acute myelogenous leukaemia stem and progenitor cells. Blood. 2007;110:4427–35. doi:https://doi.org/10.1182/blood-2007-05-090621
- Pei S, Minhajuddin M, D’Alessandro A, Nemkov T, Stevens BM, Adane B, Khan N, Hagen FK, Yadav VK, De S, et al. Rational design of a parthenolide-based drug regimen that selectively eradicates acute myelogenous leukemia stem cells. J Biol Chem. 2016;291:1984–2000.
- Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J. 1985;291:569–73. doi:https://doi.org/10.1136/bmj.291.6495.569
- Kuete V, Viertel K, Efferth T. 18-Antiproliferative potential of African medicinal plants. In Kuete V editor. Medicinal plant research in Africa. Amsterdam: Elsevier;2013. p. 711–24.
- Wang Z, Sun F, Xie S, Wang J, Li Y, Dong J, Sun M, Sun B. A new species of Garcinia (Clusiaceae) from the middle Miocene of Fujian, China, and a phytogeographic analysis. Geol J. 2019;54(3):1314–17. doi:https://doi.org/10.1002/gj.3228
- Dy Phon, Dictionary of Plants Used in Cambodia. 2000.
- Lin YF, Zhuan Y, Zhao YH. Chinese Dai Medicine Colorful Illustration. Kunming: Yunnan National Publishing House; 2003. p. 6.
- Swami SB, Thakor NJ, Patil SC. Kokum (Garcinia Indica) and its many functional components as related to the human health: A Review. J Food Res Technol. 2014;2(4):130–142.
- Ekene EN, Erhirhie EO. Garcinia kola: a review of its ethnomedicinal, chemical and pharmacological properties. Int J Cur Res Rev. 2014;06(11):1–7.
- Nguyen TH. Phytochemical and biological investigation of the bark of Garcinia fusca Pierre. PhD Thesis, 2015.
- Mandal S, Das PC, Joshi PC. Naturally occurring xanthones from terrestrial flora. J. Indian Chem. Soc. 1992;69:611–636.
- Asano J, Chiba K, Tada M, Yoshii T. Cytotoxic xanthones from Garcinia hanburyi. Phytochemistry. 1996;41(3):815–820. doi:https://doi.org/10.1016/0031-9422(95)00682-6
- Zhang H-Z, Kasibhatla S, Wang Y, Herich J, Guastella J, Tseng B, Drewe J, Cai SX. Discovery, characterization and SAR of gambogic acid as a potent apoptosis inducer by an HTS assay. Bioorg Med Chem. 2004;12(2):309–317. doi:https://doi.org/10.1016/j.bmc.2003.11.013
- Zhao L, Guo QL, You QD, Wu ZQ, Gu HY. Gambogic acid induces apoptosis and regulates expressions of Bax and Bcl-2 protein in human gastric carcinoma MGC-803 cells. Biol Pharm Bull. 2004;27:998–1003. doi:https://doi.org/10.1248/bpb.27.998
- Guo Q-L, Lin S-S, You Q-D, Gu H-Y, Yu J, Zhao L, Qi Q, Liang F, Tan Z, Wang X. Inhibition of human telomerase reverse transcriptase gene expression by gambogic acid in human hepatoma SMMC-7721 cells. Life Sci. 2006;78(11):1238–1245. doi:https://doi.org/10.1016/j.lfs.2005.06.046
- Shi X, Chen X, Li X, Lan X, Zhao C, Liu S. Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation. Clin Cancer Res. 2014;20:151–163. doi:https://doi.org/10.1158/1078-0432.CCR-13-1063
- Li X, Liu S, Huang H, Liu N, Zhao C, Liao S, et al. Gambogic acid is a tissue-specific proteasome inhibitor in vitro and in vivo. Cell Rep. 2013;3:211. doi:https://doi.org/10.1016/j.celrep.2012.11.023
- Chen R, Zhang H, Liu P, Wu X, Chen B. Gambogenic acid synergistically potentiates bortezomib-induced apoptosis in multiple myeloma. J Cancer. 2017;8(5):839–851. doi:https://doi.org/10.7150/jca.17657
- Shu WX, Chen Y, He J. Effects of gambogic acid on the regulation of nucleoporin Nup88 in HL-60 cells. Zhonghua Zhong Liu Za Zhi. 2008;30:484–9.
- Shu W, Chen Y, Li R, Wu Q, Cui G, Ke W, Chen Z. Involvement of regulations of nucleophosmin and nucleoporins in gambogic acid-induced apoptosis in Jurkat cells. Basic Clin Pharmacol Toxicol. 2008;103:530–7. doi:https://doi.org/10.1111/j.1742-7843.2008.00292.x
- Li R, Chen Y, Zeng LL, Shu WX, Zhao F, Wen L, et al. Gambogic acid induces G0/G1 arrest and apoptosis involving inhibition of SRC-3 and inactivation of Akt pathway in K562 leukaemia cells. Toxicology. 2009;262:98–105. doi:https://doi.org/10.1016/j.tox.2009.04.059
- Yang J, He S, Li S, Zhang R, Peng A, Chen L. In vitro and in vivo antiangiogenic activity of caged polyprenylated xanthones isolated from Garcinia hanburyi Hook f. Molecules. 2013;18(12):15305–15313. doi:https://doi.org/10.3390/molecules181215305
- https://www.webmd.com/vitamins/ai/ingredientmono-666/gamboge. Accessed November 2018.
- Jiang L-L, Li K, Lin Q-H, Ren J, He Z-H, Li H, Shen N, Wei P, Feng F, He M-F, et al. Gambogic acid causes fin developmental defect in zebrafish embryo partially via retinoic acid signalling. Reprod Toxicol. 2016;63:161–168. doi:https://doi.org/10.1016/j.reprotox.2016.06.004
- Shang XF, He XR, He XY, Li M, Zhang R, Fan P, Zhang Q, Jia Z. The genus Scutellaria an ethnopharmacological and phytochemical review. J Ethnopharmacol. 2010;128:279– 313. doi:https://doi.org/10.1016/j.jep.2010.01.006
- Joshee N, Thomas PS, Rao MS, Anand YK. Skullcap: Potential medicinal crop. In Janick J, Whipkey A, editors. Trends in New Crops and New Uses. Alexandria, Virginia: ASHS Press;2002. p. 580–6.
- Awad R, Arnason JT, Trudeau V, Bergeron C, Budzinski JW, Foster BC, Merali Z. Phytochemical and biological analysis of Skullcap (Scutellaria lateriflora L.): a medicinal plant with anxiolytic properties. Phytomedicine. 2003;10(8):640–649. doi:https://doi.org/10.1078/0944-7113-00374
- Li J, Yan-Hong W, Smillie TJ, Khan IA. Identification of phenolic compounds from Scutellaria lateriflora by liquid chromatography with ultraviolet photodiode array and electrospray ionization tandem mass and spectrometry. J Pharm Biomed Anal. 2012;63:120–7. doi:https://doi.org/10.1016/j.jpba.2012.01.027
- Wu X, Zhang H, Salmani JM, Fu R, Chen B. Advances of wogonin, an extract from Scutellaria baicalensis, for the treatment of multiple tumours. Onco Targets Ther. 2016;9:2935–2943.
- Xiao R, Gan M, Jiang T. Wogonoside exerts growth-suppressive effects against T acute lymphoblastic leukemia through the STAT3 pathway. Hum Exp Toxicol. 2017;36(11):1169–1176. doi:https://doi.org/10.1177/0960327116679716
- Li H, Hui H, Xu J, Yang H, Zhang X, Liu X, Zhou Y, Li Z, Guo Q, Lu N. Wogonoside induces growth inhibition and cell cycle arrest via promoting the expression and binding activity of GATA-1 in chronic myelogenous leukaemia cells. Arch Toxicol. 2016;90(6):1507–22. doi:https://doi.org/10.1007/s00204-015-1552-3
- Taverna S, Corrado C. Natural compounds: molecular weapons against leukemias. J Leuk. 2017;05(01):226. doi:https://doi.org/10.4172/2329-6917.1000226
- He L, Lu N, Dai Q, Zhao Y, Zhao L, Wang H, Li Z, You Q, Guo Q. Wogonin induced G1-cell cycle arrest by regulating Wnt/beta-catenin signalling pathway and inactivating CDK8 in human colorectal cancer carcinoma cells. Toxicology. 2013;312:36–47. doi:https://doi.org/10.1016/j.tox.2013.07.013
- Kim SJ, Kim HJ, Kim HR, Lee S-H, Cho S-D, Choi C-S, Nam J-S, Jung J-Y. Antitumour action of baicalein and wogonin in H-T29 human colorectal cancer cells. Mol Med Rep. 2012;6(6):1443–1449. doi:https://doi.org/10.3892/mmr.2012.1085
- Scott RE. Differentiation, differentiation/gene therapy and cancer. Pharmacol Ther. 1997;73:51–65. doi:https://doi.org/10.1016/S0163-7258(96)00120-9
- Tsiftsoglou AS, Pappas IS, Vizirianakis IS. Mechanisms involved in the induced differentiation of leukaemia cells. Pharmacol Ther. 2003;100:257–90. doi:https://doi.org/10.1016/j.pharmthera.2003.09.002
- Zhang K, Guo QL, You QD, Yang Y, Zhang HW, Yang L, Gu HY, Qi Q, Tan Z, Wang X. Wogonin induces the granulocytic differentiation of human NB4 promyelocytic leukaemia cells and up-regulates phospholipid scramblase1 gene expression. Cancer Science. 2008;99,4:689–695.
- Li H, Xu J, Zhou Y, Liu X, Shen L, Zhu Y, Li Z, Wang X, Guo Q, Hui H. PLSCR1/IP3R1/Ca2+ axis contributes to the differentiation of primary AML cells induced by wogonoside. Cell Death Dis. 2017;8(5):e2768. doi:https://doi.org/10.1038/cddis.2017.175
- Chen Y, Hui H, Yang H, Zhao K, Qin Y, Gu C, Wang X, Lu N, Guo Q. Wogonoside induces cell cycle arrest and differentiation by affecting expression and subcellular localization of PLSCR1 in AML cells. Blood. 2013;121:3682–3691. doi:https://doi.org/10.1182/blood-2012-11-466219
- Lee WR, Shen SC, Lin HY, Hou WC, Yang LL, Chen YC. Wogonin and fisetin induce apoptosis in human promyeloleukemic cells, accompanied by a decrease of reactive oxygen species, and activation of caspase 3 and Ca(2+)-dependent endonuclease. Biochem Pharmacol. 2002;63:225–236. doi:https://doi.org/10.1016/S0006-2952(01)00876-0
- Kumagai T, Muller CI, Desmond JC, Imai Y, Heber D, Phillip Koeffler H. Scutellaria baicalensis, a herbal medicine: anti-proliferative and apoptotic activity against acute lymphocytic leukaemia, lymphoma and myeloma cell lines. Leuk Res. 2007;31:523–530. doi:https://doi.org/10.1016/j.leukres.2006.08.019
- Yang H, Hui H, Wang Q, Li H, Zhao K, Zhou Y, Zhu Y, Wang X, You Q, Guo Q, et al. Wogonin induces cell cycle arrest and erythroid differentiation in imatinib-resistant K562 cells and primary CML cells. Oncotarget. 2014;5(18):8188–8201. doi:https://doi.org/10.18632/oncotarget.2340
- Wang Y, Miao H, Li W, Yao J, Sun Y, Li Z, Zhao L, Guo Q. CXCL12/CXCR4 axis confers adriamycin resistance to human chronic myelogenous leukaemia and oroxylin A improves the sensitivity of K562/ADM cells. Biochem Pharmacol. 2014;90(3):212–25. doi:https://doi.org/10.1016/j.bcp.2014.05.007
- Cao H, Li W, Zhou Y, Tan R, Yang Y, Zhou Y, Guo Q, Zhao L. Oroxylin a inhibits the protection of bone marrow microenvironment on CML cells through CXCL12/CXCR4/P-gp signaling pathway. Front Oncol. 2019;9:188. doi:https://doi.org/10.3389/fonc.2019.00188
- Sonoda M, Nishiyama T, Matsukawa Y, Moriyasu M. Cytotoxic activities of flavonoids from two Scutellaria plants in Chinese medicine. J Ethnopharmacol. 2004;91:65–68. doi:https://doi.org/10.1016/j.jep.2003.11.014
- Qi Q, Peng J, Liu W, You Q, Yang Y, Lu N, Wang G, Guo Q. Toxicological studies of wogonin in experimental animals. Phytother Res. 2009;23(3):417–22. doi:https://doi.org/10.1002/ptr.2645
- Zhao L, Chen Z, Zhao Q, Wang D, Hu R, You Q, Guo Q. Developmental toxicity and genotoxicity studies of wogonin. Regul Toxicol Pharmacol. 2011;60(2):212–217. doi:https://doi.org/10.1016/j.yrtph.2011.03.008
- Pietrovski EF, Rosa KA, Facundo VA, Rios K, Marques MCA, Santos ARS. Antinociceptive properties of the ethanolic extract and the triterpene 3β,6β,16β-trihidroxilup 20 (29)-ene obtained from flowers of Combretum leprosum in mice. Pharmacol. Biochem. Behav. 2006;83(1):90–99. doi:https://doi.org/10.1016/j.pbb.2005.12.010
- Ibrahim S, Bello AS, Sunusi U, Lere MY, Umar FS, Egbong UD, Nasiru H, Muhammad A. Phytochemical screening and anti-microbial activities of the leaf, stem bark and root extracts of Combretum sokodense. Bayero J Pure App Sci. 2018;10(2):11–15. doi:https://doi.org/10.4314/bajopas.v10i2.2
- de Morais Lima GR, de Sales IRP, Filho MRDC, de Jesus NZT, de Sousa Falcão H, Barbosa-Filho JM, Cabral AGS, Souto AL, Tavares JF, Batista LM. Bioactivities of the Genus Combretum (Combretaceae): a review. Molecules. 2012;17:9142–9206.
- Pettit GR, Singh SB, Niven ML, Hamel E, Schmidt JM. Antineoplastic agents, 122. Constituents of Combretum caffrum. J Nat Prod. 1987;50:386–391. doi:https://doi.org/10.1021/np50051a008
- Bath RB, Jacobs TW. Traditional herbal medicine in Transkei. J Ethnopharmacol. 1995;48:7–12. doi:https://doi.org/10.1016/0378-8741(95)01276-J
- Masika PJ, Afolayan AJ. Antimicrobial activity of some plants used for the treatment of livestock disease in the Eastern Cape, South Africa. J Ethnopharmacol. 2002;83:129–134. doi:https://doi.org/10.1016/S0378-8741(02)00242-8
- Le Grand A. Anti-infectious phytotherapy of the tree-savannah, Senegal (Western Africa) III: A review of the phytochemical substances and anti-microbial activity of 43 species. J Ethnopharmacol. 1989;25(3):315–338. doi:https://doi.org/10.1016/0378-8741(89)90037-8
- Chika A, Bello SO. Antihyperglycaemic activity of aqueous leaf extract of Combretum micranthum (Combretaceae) in normal and alloxan-induced diabetic rats. J. Ethnopharmacol. 2010;129:34–37. doi:https://doi.org/10.1016/j.jep.2010.02.008
- Bukhari SNA, Kumar GB, Revankar HM, Qin HL. Development of combretastatins as potent tubulin polymerization inhibitors. Bioorg Chem. 2017;72:130–147. doi:https://doi.org/10.1016/j.bioorg.2017.04.007
- McGown AT, Fox BW. Differential cytotoxicity of combretastatins A1 and A4 in two daunorubicin-resistant P388 cell lines. Cancer Chemother Pharmacol. 1990;26:79–81. doi:https://doi.org/10.1007/BF02940301
- Nihei Y, Suga Y, Morinaga Y, Ohishi K, Okano A, Ohsumi K, Hatanaka T, Nakagawa R, Tsuji T, Akiyama Y, et al. A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors. Jpn J Cancer Res. 1999;90(9):1016–1025., doi:https://doi.org/10.1111/j.1349-7006.1999.tb00850.x
- Nam NH. Combretastatin A-4 analogues as antimitotic antitumor agents. Curr Med Chem. 2003;10:1697–1722. doi:https://doi.org/10.2174/0929867033457151
- Pettit GR, Temple C, Narayanan VL, Varma R, Simpson MJ, Boyd MR, Rener GA, Bansal N. Antineoplastic agents 322. Synthesis of Combretastatin A-4 Prodrugs. Anti-Cancer Drug Des. 1995;10:299–309.
- Tozer GM, Kanthou C, Parkins CS, Hill SA. The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Path. 2002;83(1):21–38. doi:https://doi.org/10.1046/j.1365-2613.2002.00211.x
- Iyer S, Chaplin D, Rosenthal D, Boulares A, Li L-Y, Smulson M. Induction of apoptosis in proliferating human endothelial cells by the tumour-specific antiangiogenesis agent combretastatin A-4. Cancer Res. 1998;58:4510–4514.
- Böhle AS, Leuschner I, Kalthoff H, Henne-Bruns D. Combretastatin A-4 prodrug: a potent inhibitor of malignant hemangioendothelioma cell proliferation. Int J Cancer. 2000;87(6):838–843. doi:https://doi.org/10.1002/1097-0215(20000915)87:6<838::AID-IJC13>3.0.CO;2-7
- Nabha SM, Mohammad RM, Wall NR, Dutcher JA, Salkini BM, Pettit GR, Al-Katib AM. Evaluation of combretastatin A-4 prodrug in a non-Hodgkin’s lymphoma xenograft model: preclinical efficacy. Anticancer Drugs. 2001;12(1):57–63.
- Billard C, Menasria F, Quinney C, Faussat A, Finet J, Combes S, Kolb JP. 4-Arylcoumarin analogues of combretastatins stimulate apoptosis of leukemic cells from chronic lymphocytic leukaemia patients. Exp Hematol. 2008;36(12):1625–1633. doi:https://doi.org/10.1016/j.exphem.2008.07.008
- Provot J, Hamze A, Peyrat J, Brion J, Alami M. Discovery and hit to lead optimization of novel combretastatin A-4 analogues: dependence of C-linker length and hybridization. ACAMC. 2013;13(10):1614–1635. doi:https://doi.org/10.2174/187152061310131206162302
- Greene LM, Nathwani SM, Bright SA, Fayne D, Croke A, Gagliardi M, McElligott AM, O’Connor L, Carr M, Keely NO, et al. The vascular targeting agent combretastatin-A4 and a novel cis-restricted -lactam analogue, CA-432, induce apoptosis in human chronic myeloid leukemia cells and ex vivo patient samples including those displaying multidrug resistance. J Pharmacol Exp Ther. 2010;335:302–313. doi:https://doi.org/10.1124/jpet.110.170415
- Romagnoli R, Baraldi PG, Cruz-Lopez O, Cara CL, Carrion MD, Brancale A, Hamel E, Chen L, Bortolozzi R, Basso G, et al. Synthesis and antitumor activity of 1,5-disubstituted 1,2,4-triazoles as cis-restricted combretastatin analogues. J Med Chem. 2010;53(10):4248–4258. doi:https://doi.org/10.1021/jm100245q
- Siemann DW, Chaplin DJ, Walicke PA. A review and update of the current status of the vasculature disabling agent combretastatin-a4 phosphate (ca4p). Expert Opin Investig Drugs. 2009;18(2):189–197. doi:https://doi.org/10.1517/13543780802691068
- Petit I, Karajannis MA, Vincent L, Young L, Butler J, Hooper AT, Shido K, Steller H, Chaplin DJ, Feldman E, et al. The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death. Blood. 2008;15(4):1951–61.
- Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, Nakamura R, Tanaka T, Tomiyama H, Saito N, et al. Chemotherapy - resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 2007;25(11):1315–1321. doi:https://doi.org/10.1038/nbt1350
- Schliemann C, Bieker R, Thoennissen N, Gerss J, Liersch R, Kessler T, Büchner T, Berdel WE, Mesters RM. Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukaemia. Leukaemia. 2007;21(9):1901–1906. doi:https://doi.org/10.1038/sj.leu.2404820
- Liesveld J. Targeting myelogenous leukaemia stem cells: role of the circulation. Review Article. Front. Oncol. 2012;02:86. doi:https://doi.org/10.3389/fonc.2012.00086
- Ossenkoppele GJ, Stussi G, Maertens J, van Montfort K, Biemond BJ, Breems D, Ferrant A, Graux C, de Greef GE, Halkes CJM, et al. Addition of bevacizumab to chemotherapy in acute myeloid leukaemia at older age: a randomised phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK). Blood. 2012;120(24):4706–4711. doi:https://doi.org/10.1182/blood-2012-04-420596
- Nathan P, Zweifel M, Padhani AR, Koh DM, Ng M, Collins DJ, Harris A, Carden C, Smythe J, Fisher N, et al. Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clin Cancer Res. 2012;18(12):3428–3439. doi:https://doi.org/10.1158/1078-0432.CCR-11-3376
- Jaroch K, Karolak M, Górski P, Jaroch A, Krajewski A, Ilnicka A, Sloderbach A, Stefański T, Stanisław S. Combretastatins: in vitro structure-activity relationship, mode of action and current clinical status. Pharmacol Rep. 2016;68:1266–1275. doi:https://doi.org/10.1016/j.pharep.2016.08.007
- Thornburg CC, Britt JR, Evans JR, Akee RK, Whitt JA, Trinh SK, Harris MJ, Thompson JR, Ewing TL, Shipley SM, et al. NCI program for natural product discovery: a publicly-accessible library of natural product fractions for high-throughput screening. ACS Chem Biol. 2018;13(9):2484–2497. doi:https://doi.org/10.1021/acschembio.8b00389
- Uckun FM, Cogle CR, Lin TL, Qazi S, Trieu VN, Schiller G, Watts JM. A phase 1B clinical study of combretastatin A1 diphosphate (OXi4503) and cytarabine (ARA-C) in combination (OXA) for patients with relapsed or refractory acute myeloid leukemia. Cancers (Basel). 2019;12(1):74. doi:https://doi.org/10.3390/cancers12010074
- Ding Y, Yang Z, Ge W, Kuang B, Xu J, Yang J, Chen Y, Zhang Q. Synthesis and biological evaluation of dithiocarbamate esters of parthenolide as potential anti-acute myelogenous leukaemia agents. J Enzyme Inhib Med Chem. 2018;33(1):1376–1391. doi:https://doi.org/10.1080/14756366.2018.1490734
- Błach-Olszewska Z, Lamer-Zarawska E. Come back to root – therapeutic activities of Scutellaria baicalensis root in aspect of innate immunity regulation – part I. Adv Clin Exp Med. 2008;17:3, 337–345.